Bladder Cancer named the official journal of the Bladder Cancer Advocacy Network (BCAN)
January 16, 2018
Amsterdam, NL and Bethesda, US – IOS Press, an international scientific, technical and medical publisher, and the Bladder Cancer Advocacy Network (BCAN), are pleased to announce that the journal Bladder Cancer is now the official journal of BCAN.
As the result of this new partnership, Bladder Cancer and BCAN will combine resources to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities. As such, the journal is dedicated to providing an open forum for publishing original peer-reviewed research in basic science, translational research and clinical medicine that will improve the fundamental understanding of bladder cancer and lead to more effective treatment of tumors of the bladder and upper urinary tract and improved patient outcomes.
“We are very excited by our new partnership with BCAN, which will enable us to further enhance Bladder Cancer’s reputation, share significant scientific advancements with a wider global audience, expand the journal’s communities of readers and contributors, and support important advocacy efforts,” commented Editors-in-Chief Seth P. Lerner, MD, Baylor College of Medicine, and Dan Theodorescu, MD, PhD, University of Colorado Cancer Center.
Launched in 2015, Bladder Cancer is an international multidisciplinary journal designed to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. Guided by an eminent editorial board comprised of global leaders in the field, the journal publishes research reports, reviews, short communications, letters-to-the-editor, and special features that deliver timely commentary, alerts of groundbreaking research, clinical trials coverage, challenging case studies and access to current funding information.
Bladder cancer is the sixth most common cancer in the United States with over 79,000 new cases and nearly 17,000 deaths that were projected for 2017. With only recent advances in treatments over the past 30 years, there continues to be a tremendous need for more bladder cancer research. BCAN CEO Andrea Maddox-Smith notes, “Peer-reviewed scientific journals like Bladder Cancer represent the most vital means for disseminating research findings to ultimately improve the lives and outcomes for bladder cancer patients. We enthusiastically look forward to the many scientific achievements that will be documented in this publication, and we are very excited to be able to announce Bladder Cancer as the official journal of the Bladder Cancer Advocacy Network.”
About IOS Press
IOS Press (iospress.com) is headquartered in Amsterdam with satellite offices in the USA, Germany, India and China and serves the information needs of scientific and medical communities worldwide. Established in 1987, IOS Press now publishes over 100 international journals and about 75 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences. bladdercancerjournal.com
About the Bladder Cancer Advocacy Network
BCAN is the leading voice for bladder cancer in the US, providing resources to not only those diagnosed with the disease but their families, caregivers and the medical community united in support of people touched by the disease. The organization is setting the agenda for bladder cancer by promoting and funding collaborative, cutting-edge research programs, and providing critical patient support and education services. Each year, it provides thousands of patients, caregivers and the medical community with the educational resources and support services they need to navigate their bladder cancer journey. For more information go to bcan.org or call 1-888-901-BCAN (2226).
Name: Camel McNamara, PhD, IOS Press
Tel: +31 20 688 3355
Name: Stephanie Chisolm, PhD, Bladder Cancer Advocacy Network (BCAN)
Tel: +1 301 215 9099